Topic Hub
11 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 11 of 11 clinical reviews.
How common is constipation on Wegovy? Trial-level incidence data, severity breakdown, risk factors, typical timeline, and when to call your prescriber.
Read clinical reviewA phase-by-phase breakdown of when constipation starts, peaks, and typically resolves during Wegovy dose escalation, backed by STEP trial data and GI motility research.
Read clinical reviewSpecific dietary changes, hydration targets, meal-timing strategies, and evidence-backed supplements that reduce constipation caused by Wegovy (semaglutide 2.4 mg).
Read clinical reviewEvidence-based dietary strategies to relieve constipation caused by Wegovy (semaglutide 2.4 mg), including fiber protocols, hydration targets, and foods to prioritize or avoid.
Read clinical reviewA clinically specific, step-by-step protocol for assessing and treating constipation caused by Wegovy (semaglutide 2.4 mg), including first-line interventions, escalation criteria, and discontinuation triggers.
Read clinical reviewOTC and prescription options for treating constipation caused by Wegovy (semaglutide 2.4 mg), including first-line osmotic laxatives, second-line prokinetics, drug interactions to avoid, and when to escalate care.
Read clinical reviewLearn when constipation from Wegovy (semaglutide 2.4 mg) requires medical attention, why GLP-1 agonists slow gut transit, and how to manage this common side effect safely.
Read clinical reviewPersistent constipation on Wegovy (semaglutide 2.4 mg) affects up to 24% of patients. Learn why it happens, when to worry, and clinician-backed strategies to restore normal bowel function.
Read clinical reviewClinical criteria for discontinuing Wegovy due to constipation, including severity thresholds, lab red flags, quality-of-life impact, and alternative GLP-1 options.
Read clinical reviewClinical explanation of how semaglutide slows gut transit time across the entire GI tract, causing constipation in Wegovy patients, with actionable management steps.
Read clinical reviewA clinical deep-dive into how semaglutide 2.4 mg slows gut motility and causes constipation, including the GLP-1 receptor pathways involved, trial data from STEP-1 through STEP-5, and evidence-based management strategies.
Read clinical review